Todd M. Wilson, D.O.Building 10, Room 11C20710 Center DriveBethesda, MD 20892-1881Phone: 301-496-8772Fax: email@example.com
Clinical Transition Fellow, Mast Cell Biology Section, LAD
Dr. Wilson received his D.O. from the New York College of Osteopathic Medicine and completed his internal medicine residency at the University of Medicine and Dentistry of New Jersey in Newark. Dr. Wilson joined NIAID as a clinical fellow in allergy and immunology in 2004 and is presently an assistant clinical investigator in the NIAID Transition Program in Clinical Research within the Mast Cell Biology Section.
Wilson TM, Maric I, Shukla J, Brown M, Santos C, Simakova O, Khoury P, Fay MP, Kozhich A, Kolbeck R, Metcalfe DD, Klion AD. IL-5 receptor alpha levels in patients with marked eosinophilia or mastocytosis. J Allergy Clin Immunol. 2011 Nov;128(5):1086-92.e1-3.
Wilson TM, Maric I, Simakova O, Bai Y, Chan EC, Olivares N, Carter M, Maric D, Robyn J, Metcalfe DD. Clonal analysis of NRAS activating mutations in KIT-D816V systemic mastocytosis. Haematologica. 2011 Mar;96(3):459-63.
Martinez B, Metcalfe DD, Wilson TM. Chapter 25: Systemic mastocytosis. In: Kaplan A, Greaves M, editors., Urticaria and angioedema. 2nd ed. Informa Healthcare Publications; c2009. p. 409-23.
Lahortiga I, Akin C, Cools J, Wilson TM, Mentens N, Arthur DC, Maric I, Noel P, Kocabas C, Marynen P, Lessin LS, Wlodarska I, Robyn J, Metcalfe DD. Activity of imatinib in systemic mastocytosis with chronic basophilic leukemia and a PRKG2-PDGFRB fusion. Haematologica. 2008 Jan;93(1):49-56.
Maric I, Robyn J, Metcalfe DD, Fay MP, Carter M, Wilson T, Fu W, Stoddard J, Scott L, Hartsell M, Kirshenbaum A, Akin C, Nutman TB, Noel P, Klion AD. KIT D816V-associated systemic mastocytosis with eosinophilia and FIP1L1/PDGFRA-associated chronic eosinophilic leukemia are distinct entities. J Allergy Clin Immunol. 2007 Sep;120(3):680-7.
Visit PubMed for a complete publication listing.
back to top
Last Updated February 13, 2013
Last Reviewed February 13, 2013